175 related articles for article (PubMed ID: 22005789)
1. Role of stromal microenvironment in nonpharmacological resistance of CML to imatinib through Lyn/CXCR4 interactions in lipid rafts.
Tabe Y; Jin L; Iwabuchi K; Wang RY; Ichikawa N; Miida T; Cortes J; Andreeff M; Konopleva M
Leukemia; 2012 May; 26(5):883-92. PubMed ID: 22005789
[TBL] [Abstract][Full Text] [Related]
2. Association between imatinib-resistant BCR-ABL mutation-negative leukemia and persistent activation of LYN kinase.
Wu J; Meng F; Kong LY; Peng Z; Ying Y; Bornmann WG; Darnay BG; Lamothe B; Sun H; Talpaz M; Donato NJ
J Natl Cancer Inst; 2008 Jul; 100(13):926-39. PubMed ID: 18577747
[TBL] [Abstract][Full Text] [Related]
3. CXCR4 up-regulation by imatinib induces chronic myelogenous leukemia (CML) cell migration to bone marrow stroma and promotes survival of quiescent CML cells.
Jin L; Tabe Y; Konoplev S; Xu Y; Leysath CE; Lu H; Kimura S; Ohsaka A; Rios MB; Calvert L; Kantarjian H; Andreeff M; Konopleva M
Mol Cancer Ther; 2008 Jan; 7(1):48-58. PubMed ID: 18202009
[TBL] [Abstract][Full Text] [Related]
4. Combination of imatinib with CXCR4 antagonist BKT140 overcomes the protective effect of stroma and targets CML in vitro and in vivo.
Beider K; Darash-Yahana M; Blaier O; Koren-Michowitz M; Abraham M; Wald H; Wald O; Galun E; Eizenberg O; Peled A; Nagler A
Mol Cancer Ther; 2014 May; 13(5):1155-69. PubMed ID: 24502926
[TBL] [Abstract][Full Text] [Related]
5. PD166326, a novel tyrosine kinase inhibitor, has greater antileukemic activity than imatinib mesylate in a murine model of chronic myeloid leukemia.
Wolff NC; Veach DR; Tong WP; Bornmann WG; Clarkson B; Ilaria RL
Blood; 2005 May; 105(10):3995-4003. PubMed ID: 15657179
[TBL] [Abstract][Full Text] [Related]
6. Lyn regulates BCR-ABL and Gab2 tyrosine phosphorylation and c-Cbl protein stability in imatinib-resistant chronic myelogenous leukemia cells.
Wu J; Meng F; Lu H; Kong L; Bornmann W; Peng Z; Talpaz M; Donato NJ
Blood; 2008 Apr; 111(7):3821-9. PubMed ID: 18235045
[TBL] [Abstract][Full Text] [Related]
7. A novel co-operative mechanism linking TGFβ and Lyn kinase activation to imatinib resistance in chronic myeloid leukaemia cells.
Smith PG; Tanaka H; Chantry A
Oncotarget; 2012 May; 3(5):518-24. PubMed ID: 22643838
[TBL] [Abstract][Full Text] [Related]
8. Effects of plerixafor in combination with BCR-ABL kinase inhibition in a murine model of CML.
Agarwal A; Fleischman AG; Petersen CL; MacKenzie R; Luty S; Loriaux M; Druker BJ; Woltjer RL; Deininger MW
Blood; 2012 Sep; 120(13):2658-68. PubMed ID: 22889761
[TBL] [Abstract][Full Text] [Related]
9. Overexpression of heme oxygenase-1 in bone marrow stromal cells promotes microenvironment-mediated imatinib resistance in chronic myeloid leukemia.
Liu P; Ma D; Yu Z; Zhe N; Ren M; Wang P; Yu M; Huang J; Fang Q; Wang J
Biomed Pharmacother; 2017 Jul; 91():21-30. PubMed ID: 28445830
[TBL] [Abstract][Full Text] [Related]
10. Crosstalk between BCR/ABL oncoprotein and CXCR4 signaling through a Src family kinase in human leukemia cells.
Ptasznik A; Urbanowska E; Chinta S; Costa MA; Katz BA; Stanislaus MA; Demir G; Linnekin D; Pan ZK; Gewirtz AM
J Exp Med; 2002 Sep; 196(5):667-78. PubMed ID: 12208881
[TBL] [Abstract][Full Text] [Related]
11. Cotreatment with vorinostat (suberoylanilide hydroxamic acid) enhances activity of dasatinib (BMS-354825) against imatinib mesylate-sensitive or imatinib mesylate-resistant chronic myelogenous leukemia cells.
Fiskus W; Pranpat M; Balasis M; Bali P; Estrella V; Kumaraswamy S; Rao R; Rocha K; Herger B; Lee F; Richon V; Bhalla K
Clin Cancer Res; 2006 Oct; 12(19):5869-78. PubMed ID: 17020995
[TBL] [Abstract][Full Text] [Related]
12. Plerixafor inhibits chemotaxis toward SDF-1 and CXCR4-mediated stroma contact in a dose-dependent manner resulting in increased susceptibility of BCR-ABL+ cell to Imatinib and Nilotinib.
Dillmann F; Veldwijk MR; Laufs S; Sperandio M; Calandra G; Wenz F; Zeller J; Fruehauf S
Leuk Lymphoma; 2009 Oct; 50(10):1676-86. PubMed ID: 19657955
[TBL] [Abstract][Full Text] [Related]
13. [Role of Lyn kinase in imatinib-resistant chronic myelogenous leukemia].
Liu J; Zhao XL
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2012 Dec; 20(6):1352-5. PubMed ID: 23257431
[TBL] [Abstract][Full Text] [Related]
14. Expression of a Src family kinase in chronic myelogenous leukemia cells induces resistance to imatinib in a kinase-dependent manner.
Pene-Dumitrescu T; Smithgall TE
J Biol Chem; 2010 Jul; 285(28):21446-57. PubMed ID: 20452982
[TBL] [Abstract][Full Text] [Related]
15. Effective and selective inhibition of chronic myeloid leukemia primitive hematopoietic progenitors by the dual Src/Abl kinase inhibitor SKI-606.
Konig H; Holyoake TL; Bhatia R
Blood; 2008 Feb; 111(4):2329-38. PubMed ID: 18056843
[TBL] [Abstract][Full Text] [Related]
16. Use of dasatinib and nilotinib in imatinib-resistant chronic myeloid leukemia: translating preclinical findings to clinical practice.
DeAngelo DJ; Attar EC
Leuk Lymphoma; 2010 Mar; 51(3):363-75. PubMed ID: 20038231
[TBL] [Abstract][Full Text] [Related]
17. Targeted drugs in chronic myeloid leukemia.
Gora-Tybor J; Robak T
Curr Med Chem; 2008; 15(29):3036-51. PubMed ID: 19075651
[TBL] [Abstract][Full Text] [Related]
18. Evidence that resistance to nilotinib may be due to BCR-ABL, Pgp, or Src kinase overexpression.
Mahon FX; Hayette S; Lagarde V; Belloc F; Turcq B; Nicolini F; Belanger C; Manley PW; Leroy C; Etienne G; Roche S; Pasquet JM
Cancer Res; 2008 Dec; 68(23):9809-16. PubMed ID: 19047160
[TBL] [Abstract][Full Text] [Related]
19. Overcoming kinase resistance in chronic myeloid leukemia.
Lee F; Fandi A; Voi M
Int J Biochem Cell Biol; 2008; 40(3):334-43. PubMed ID: 18401881
[TBL] [Abstract][Full Text] [Related]
20. Establishment of a murine model for therapy-treated chronic myelogenous leukemia using the tyrosine kinase inhibitor STI571.
Wolff NC; Ilaria RL
Blood; 2001 Nov; 98(9):2808-16. PubMed ID: 11675355
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
